GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

"CH and New GSK are two strong businesses that the market currently values far below their true potential. In our view, they warrant a combined valuation >45% higher than GSK's valuation today ...

but Novartis has a very strong track record in maximising the value from cancer drugs, including extending licences into new niche therapy areas. Novartis also has opt-in rights for GSK's current ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

This is one of GSK’s main value drivers at this stage ... This segment also grew, mainly due to their expanded approvals for new indications in the US and Europe. Lastly, GSK’s general ...

We are holding firm to GSK’s fair value estimate and continue to view the stock as undervalued with the market likely missing the firm’s growth potential, partially driven by new products like ...

PFG Investments LLC lifted its position in GSK plc (NYSE:GSK – Free Report) by 8.5% in the 3rd quarter, Holdings Channel.com ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

This dividend stock looks attractive, offering a 4% yield and trading well below our $54 fair value estimate. GSK lands on Morningstar ... in development costs per new drug.